Joseph C. Wu
Academic Appointments
- Professor, Medicine - Cardiovascular Medicine
- Member, Stanford Cancer Institute
- Member, Bio-X
- Professor, Radiology
Key Documents
Contact Information
-
Clinical Offices
Cardiovascular Medicine Clinic 300 Pasteur Dr MC 5319 A260 Stanford, CA 94305 Tel Work (650) 723-6145 Fax (650) 723-8392
- Academic Offices
Personal Information EmailAdministrative Contact Susan Singh 265 Campus Drive, G1120B, Stanford, CA 94305-5454 Email Tel Work 650-736-9781Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Congenital Heart Disease (Adult)
- Cardiovascular Disease
Administrative Appointments
- Co-Director, Stanford Cardiovascular Institute (2013 - present)
- Editorial Board, Journal Clinical Investigation (2012 - present)
- Editorial Board, Circulation Research (2011 - present)
- Editorial Board, Stem Cell Research (2011 - present)
- Editorial Board, Molecular Therapy (2011 - present)
- Editorial Board, Human Gene Therapy (2009 - present)
Honors and Awards
- American Heart Association Established Investigator Award, AHA EIA (2013-2017)
- Elected to Association of University Cardiologists, AUC (2013)
- Elected to American Society Clinical Investigators, ASCI (2012)
- Bernard and Joan Marshall Research Excellence Prize, British Society for Cardiovascular Research (2011)
- Presidential Early Career Award for Scientists and Engineers (PECASE), White House Office of Technology (2010)
- NIH Transformative R01 Award, National Institutes of Health (2009-2014)
Professional Education
| Fellowship: | UCLA Medical Center CA (2004) |
| Board Certification: | Echocardiography, National Board of Echocardiography (2004) |
| Board Certification: | Cardiovascular Disease, American Board of Internal Medicine (2004) |
| Residency: | UCLA Medical Center CA (1999) |
| Medical Education: | Yale University School of Medicine-Graduate CT (1997) |
| MD: | Yale University, Medicine (1997) |
Postdoctoral Advisees
Paul Burridge, Wen-Yi Chen, Jared Churko, Sebastian Diecke, Antje Ebert, Mingxia Gu, chunjiang He, Shijun Hu, Kazuki Kodo, Nigel Kooreman, Feng Lan, Jaecheol Lee, Won Hee Lee, Ping Liang, Shin Lin, Elena Matsa, Nicholas Mordwinkin, Sang Ging Ong, Jordan Plews, Johannes Riegler, PRAVEEN KUMAR SHUKLA, Veronica Sanchez Freire, Ning Sun, Wenchao Sun, Evangeline Tzatzalos, Yongming Wang, HaoDi Wu, Yan Zhang
Graduate & Fellowship Program Affiliations
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
My lab works on biological mechanisms of adult stem cells, embryonic stem cells, and induced pluripotent stem cells. We use a combination of gene profiling, tissue engineering, physiological testing, and molecular imaging technologies to better understand stem cell biology in vitro and in vivo. For adult stem cells, we are interested in monitoring stem cell survival, proliferation, and differentiation. For ESC, we are currently studying their tumorigenicity, immunogenicity, and differentiation. For iPSC, we are working on novel derivation techniques. We also work on development of novel vectors and therapeutic genes for cardiovascular gene therapy applications.
Clinical Trials
- Recruiting Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy
- Recruiting An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
- Recruiting AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction
Publications
- Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013; (1): 101-13
- Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013; (16): 1677-91
- Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012; (130): 130ra47
- Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012; (1): 16-28
- An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol. 2011; (9): 829-34
- Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell. 2011; (3): 309-17
Help